Cargando…
Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches
Behçet's uveitis (BU) is a debilitating manifestation of Behçet's disease, often requiring prompt and aggressive treatment to prevent vision loss. Glucocorticoids (GCS) serve as a first-line therapy for BU; however, their long-term, high-dose use can result in significant adverse effects....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520171/ https://www.ncbi.nlm.nih.gov/pubmed/37420127 http://dx.doi.org/10.1007/s10792-023-02808-w |
_version_ | 1785109855575474176 |
---|---|
author | Li, Biao Li, Haoran Huang, Qun Zheng, Yanlin |
author_facet | Li, Biao Li, Haoran Huang, Qun Zheng, Yanlin |
author_sort | Li, Biao |
collection | PubMed |
description | Behçet's uveitis (BU) is a debilitating manifestation of Behçet's disease, often requiring prompt and aggressive treatment to prevent vision loss. Glucocorticoids (GCS) serve as a first-line therapy for BU; however, their long-term, high-dose use can result in significant adverse effects. This review summarizes the efficacy, adverse effects, and advances in combination therapy involving GCS for the management of BU. We discuss the benefits and drawbacks of various GCS administration routes, including periocular and intravitreal injections, intravitreal sustained-release devices, and systemic therapy, highlighting the role of fluocinolone acetonide and dexamethasone as primary sustained-release formulations. Moreover, we underscore the importance of combining GCS with immunosuppressive drugs and biological agents to minimize adverse reactions and optimize therapeutic outcomes. The review concludes that, while GCS remain a crucial component of BU treatment, careful consideration of their administration and combination with other therapies is essential to achieve long-term remission and improved visual outcomes for patients with BU. |
format | Online Article Text |
id | pubmed-10520171 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-105201712023-09-27 Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches Li, Biao Li, Haoran Huang, Qun Zheng, Yanlin Int Ophthalmol Review Behçet's uveitis (BU) is a debilitating manifestation of Behçet's disease, often requiring prompt and aggressive treatment to prevent vision loss. Glucocorticoids (GCS) serve as a first-line therapy for BU; however, their long-term, high-dose use can result in significant adverse effects. This review summarizes the efficacy, adverse effects, and advances in combination therapy involving GCS for the management of BU. We discuss the benefits and drawbacks of various GCS administration routes, including periocular and intravitreal injections, intravitreal sustained-release devices, and systemic therapy, highlighting the role of fluocinolone acetonide and dexamethasone as primary sustained-release formulations. Moreover, we underscore the importance of combining GCS with immunosuppressive drugs and biological agents to minimize adverse reactions and optimize therapeutic outcomes. The review concludes that, while GCS remain a crucial component of BU treatment, careful consideration of their administration and combination with other therapies is essential to achieve long-term remission and improved visual outcomes for patients with BU. Springer Netherlands 2023-07-07 2023 /pmc/articles/PMC10520171/ /pubmed/37420127 http://dx.doi.org/10.1007/s10792-023-02808-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Li, Biao Li, Haoran Huang, Qun Zheng, Yanlin Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches |
title | Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches |
title_full | Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches |
title_fullStr | Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches |
title_full_unstemmed | Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches |
title_short | Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches |
title_sort | optimizing glucocorticoid therapy for behçet's uveitis: efficacy, adverse effects, and advances in combination approaches |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520171/ https://www.ncbi.nlm.nih.gov/pubmed/37420127 http://dx.doi.org/10.1007/s10792-023-02808-w |
work_keys_str_mv | AT libiao optimizingglucocorticoidtherapyforbehcetsuveitisefficacyadverseeffectsandadvancesincombinationapproaches AT lihaoran optimizingglucocorticoidtherapyforbehcetsuveitisefficacyadverseeffectsandadvancesincombinationapproaches AT huangqun optimizingglucocorticoidtherapyforbehcetsuveitisefficacyadverseeffectsandadvancesincombinationapproaches AT zhengyanlin optimizingglucocorticoidtherapyforbehcetsuveitisefficacyadverseeffectsandadvancesincombinationapproaches |